期刊文献+

消癌平对非小细胞肺癌厄洛替尼耐药的逆转作用 被引量:7

The Experimental Studies of Xiaoaiping Injection on the Reversal of Erlotinib Resistance in non-small cell lung cancer
下载PDF
导出
摘要 目的:研究消癌平对厄洛替尼非小细胞肺癌(NSCLC)耐药细胞株PC9/G2的逆转作用机制。方法:MTT法考察消癌平对PC9/G2非毒性剂量,以及对厄洛替尼NSCLC耐药的逆转效应;RT-PCR法测定消癌平对EGFR下游通路PI3K mRNA表达水平的影响,Western blot法测定PI3K蛋白水平变化,分光光度法测定凋亡蛋白Caspase-3活性的变化。结果:消癌平对PC9/G2的非毒性剂量为10mg/mL;消癌平联合厄洛替尼组有明显的逆转耐药作用,细胞存活率比对照组(单用厄洛替尼)降低15%~23%;消癌平使PI3K mRNA和蛋白表达水平显著下降,Caspase-3凋亡蛋白活性提高。结论:消癌平对厄洛替尼NSCLC耐药有逆转作用,可能通过抑制PI3K表达,进而激活凋亡蛋白Caspase-3的机制实现。 Objective: To investigate the effect and its mechanism of Xiaoaiping injection on the reversal of Erlotinib resistance in non-small lung cancer cell line PC9/G2. Methods: The non-toxic dosage of PC9/G2 to Xiaoaiping injection and the reversal of drug resistance were determined with MTT method. The expression of PI3K mRNA was tested with RT-PCR. The level of PI3K protein was tested with Western blot. The activity of apoptosis proteins Caspase-3 was determined with spectrophotometry. Results:The non-toxic dosage of PC9/G2 to Xiaoaiping injection was 10mg/mL. The cell survival rate decreased 15%~23%in Xiaoaipin injection combining Erlotinib group compared with Erlotinib group. The expression of PI3K mRNA and protein dropped significantly, and Caspase-3 apoptosis proteins activity increased significantly. Conclusion: Xiaoaiping injection could reverse the Erlotinib resistance cell line PC9/G2 in a certain extent,which may be attributed to down regulating of PI3K expression and inducing more apoptosis proteins Caspase-3.
出处 《药品评价》 CAS 2014年第6期30-34,共5页 Drug Evaluation
基金 "ERCC1 RRM1和BRCA1表达水平与晚期NSCLC化疗反应的相关性研究"。浙江省医药卫生科技计划项目 编号:2010KYA07
关键词 消癌平 厄洛替尼耐药 逆转 机制 Xiaoaiping Injection Erlotinib Resistance Reversion Mechanism
  • 相关文献

参考文献10

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CACancer J Clin, 2009, 59: 225-249.
  • 2Riely G J, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon I9 and 21 mutations treated with gefitinib or er[otinib[J]. Clin Cancer Res, 2006, 12: 839-845.
  • 3Okabe T, Okamoto 1, Tsukioka S, et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification[J]. Clin Cancer Res, 2009, 15:907-913.
  • 4Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an erreversible EGFR inhibitor[J]. Oncogene, 2010, 29: 2346-235l.
  • 5王文玉,周云,张晓菊,高天慧,罗执芬,刘明月.消癌平注射液联合化疗治疗晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2009,14(10):936-938. 被引量:34
  • 6陈同生,王小平,王治平,王龙祥,王会营,邢达.消癌平诱导人肺腺癌(ASTC-a-1)细胞内caspase-3活化的荧光光谱分析[J].光谱学与光谱分析,2008,28(6):1327-1331. 被引量:12
  • 7粟波,苏春霞,张海平,邓沁芳,赵印敏,周彩存.吉非替尼耐药细胞株的筛选和基因谱表达研究[J].肿瘤,2008,28(7):552-557. 被引量:9
  • 8Felip E, Cedres S, Peralta S, etal. Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)[J]. Ann Oncol, 2007, 18: ix 143-153.
  • 9Hu Y, Shen X, Lu H, et al. Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells[J]. J Nat Prod, 2008, 71: 1049-1059.
  • 10Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefetinib (Iressa)[J]. Br J Cancer, 2005, 92 (9): 1711-1719.

二级参考文献30

共引文献49

同被引文献104

引证文献7

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部